Heyu Biological Technology Corporation
HYBT
Other OTC0.35
USD
-0.25
- -
CIK
0001086303
ISIN
US42831T1034
CUSIP
42831T103
Return %
Stock
S&P500
1Y
2,816.67
26.53
3Y
188.30
76.60
5Y
191.67
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ban Siong Ang
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Baotuo Building Xiamen People's Republic of China 361009
- IPO Date
- Dec 6, 1999
- CIK
- 0001086303
- Website
- heyubt.com
- Similar Companies
- Business
- Heyu Biological Technology Corporation is a holding company primarily engaged in the research, development, and manufacturing of high-technology medical equipment through its subsidiaries operating in China. The company’s core product offerings include medical devices such as the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber, a medical equipment designed for cancer treatment by leveraging cold nuclear fusion stimulated by cosmic ray muons. Heyu operates its business mainly through its Chinese subsidiaries, including Jiashierle (Xiamen) Healthcare Technology Co., Ltd., which holds a substantial equity interest in Shanghai Kangzi Medical Technology Co., Ltd., responsible for the R&D and production of its medical technology products. The company also previously engaged in agreements for raspberry juice processing but does not intend to continue in that segment. Heyu targets both individual and institutional customers within China, aiming to expand production and market its medical equipment across various cities with plans for establishing operational centers and related services. Founded in 1987 and headquartered in Nevada, U.S., Heyu conducts substantial operations in China with ownership structures involving entities in the British Virgin Islands and Hong Kong. Recent major changes include the completion of mergers and acquisitions, notably the acquisition of full ownership of Hong Chang Biotechnologies (HK) Limited and a strategic refocus following the suspension of R&D activities due to the COVID-19 pandemic and funding limitations. Heyu’s latest strategic activities involve advancing clinical trials for the Submillimeter Wave Therapy Chamber in cooperation with Shenzhen Saikun Biotechnology Co., Ltd., and plans to obtain governmental permits for mass production and national sales in China. The company also experienced corporate governance developments, including board reappointments and share restructuring through reverse and forward stock splits. Heyu continues to evaluate the resumption of R&D activities and navigate regulatory challenges stemming from operating within the Chinese market, including compliance with foreign investment laws and cybersecurity regulations affecting Chinese enterprises listed overseas. Heyu Biological Technology Corporation’s business segments include smart health and smart hospital technologies, internet healthcare services, production and sale of medical devices, and the development of advanced therapy chambers. Its operations are characterized by conducting R&D, manufacturing, clinical trials, and commercialization of medical equipment mainly in China, supported by a corporate structure spanning Nevada, Hong Kong, and the British Virgin Islands holding companies. The company focuses on leveraging innovative medical technology for cancer treatment and health management, aiming for expansion in the Chinese healthcare market and subsequent scaling of its proprietary technology commercialization. Heyu maintains a complex ownership and operational structure with the holding company in Nevada and subsidiaries across Asia, including full ownership of HP Technology Limited (British Virgin Islands), Heyu Healthcare Technology Limited (Hong Kong), Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (PRC), and equity participation in Shanghai Kangzi Medical Technology Co., Ltd. The company faces operational risks due to regulatory and legal uncertainties in China but continues to advance its technology development and clinical trial implementation in partnership with local biotech firms and hospitals. Heyu Biological Technology Corporation, listed under ticker HYBT, actively manages regulatory compliance and market expansion challenges tied to its China-based operations, with a specific focus on novel medical technologies for cancer treatment, operating since 1987 with a continuous effort to develop and commercialize advanced healthcare equipment and services across its target markets in China and related regions. Recent partnerships and acquisitions underline its strategic shift toward consolidating biotech assets and enhancing clinical trial activities ahead of larger-scale product commercialization.